Most cited papers from Genmab (United States)

Genmab (United States)

What are the most cited papers from Genmab (United States)?

The most cited paper from Genmab (United States) is "Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma" (Thierry T.F. Facon et al., 2019), with 1,022 citations. Next come "Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study" (973) and "Immunoglobulin G4: an odd antibody" (836).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 66 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Thierry T.F. Facon et al. · New England Journal of Medicine Open access	29 May 2019	1,022
2	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Philippe Moreau et al. · The Lancet Open access	3 Jun 2019	973
3	Immunoglobulin G4: an odd antibody Rob C. Aalberse, Steven O. Stapel, Janine Schuurman et al. · Clinical & Experimental Allergy	16 Feb 2009	836
4	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Efstathios Kastritis et al. · New England Journal of Medicine Open access	30 Jun 2021	703
5	Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial Catherine Thiéblemont et al. · Journal of Clinical Oncology Open access	22 Dec 2022	577
6	Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma Pieter Sonneveld et al. · New England Journal of Medicine Open access	12 Dec 2023	574
7	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques Ann Jones Hessell, Pascal Poignard, Meredith Hunter et al. · Nature Medicine Open access	7 Jun 2009	553
8	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma Marije B. Overdijk, Sandra A.B.W. Verploegen, Marijn Bögels et al. · mAbs Open access	4 Mar 2015	517
9	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Robert Louis Coleman et al. · The Lancet Oncology	9 Apr 2021	410
10	Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial Thierry T.F. Facon et al. · The Lancet Oncology Open access	14 Oct 2021	375
11	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet Open access	Sep 2021	349
12	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial Meletios Athanasios Dimopoulos et al. · The Lancet Oncology Open access	Jun 2021	340
13	Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1 Marjan Hezareh, Ann Jones Hessell, Richard Christian Jensen et al. · Journal of Virology Open access	15 Dec 2001	305
14	Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo Aran F. Labrijn, Antonio Ortiz Buijsse, Ewald T.J. van den Bremer et al. · Nature Biotechnology	20 Jul 2009	296
15	Targeting interleukin‐15 in patients with rheumatoid arthritis: A proof‐of‐concept study Bo Baslund, N. Tvede, Bente Danneskiold‐Samsøe et al. · Arthritis & Rheumatism	Sep 2005	266
16	Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR Andrew G Spencer et al. · Haematologica Open access	20 Sep 2018	262
17	Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial María‐Victoria Mateos et al. · The Lancet Haematology Open access	23 Mar 2020	251
18	Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy Jeremy Baldwin et al. · Cell Open access	13 Sep 2024	247
19	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial Johann Sebastian De Bono et al. · The Lancet Oncology Open access	10 Feb 2019	238
20	Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage Tanja Schneider‐Merck, Jeroen J. Lammerts van Bueren, Sven Berger et al. · The Journal of Immunology Open access	30 Nov 2009	223
21	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab Michael S. van der Veer, Michel de Weers, Berris van Kessel et al. · Haematologica Open access	25 Nov 2010	219
22	Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX Meletios Athanasios Dimopoulos et al. · Haematologica Open access	20 Sep 2018	210
23	In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation Dhaya Seshasayee et al. · Journal of Clinical Investigation Open access	3 Dec 2007	206
24	Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose Michael J. Gramer, Jackie J. Eckblad, Ruth Donahue et al. · Biotechnology and Bioengineering	15 Feb 2011	193
25	Significant impact of cutaneous T‐cell lymphoma on patients' quality of life Marie‐France Demierre, Stephanie D. Gan, Judy M. Jones et al. · Cancer Open access	17 Oct 2006	184
26	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial Philippe Moreau et al. · The Lancet Oncology Open access	13 Sep 2021	180
27	Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations Bilal Mohty, J. El-Cheikh, Ibrahim Yakoub‐Agha et al. · Haematologica Open access	Feb 2010	168
28	Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study Kim Linton et al. · The Lancet Haematology Open access	15 Jun 2024	165
29	High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action Homer Adams, Frederik Stevenaert, Jakub Krejcik et al. · Cytometry Part A Open access	11 Dec 2018	164
30	When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy Marlies Oostendorp, Jeroen J. Lammerts van Bueren, Parul D Doshi et al. · Transfusion Open access	18 May 2015	160
31	Complement activation by (auto-) antibodies Nina A. Daha, Nirmal K. Banda, Anja Roos et al. · Molecular Immunology	25 Jul 2011	150
32	Controlled Fab-arm exchange for the generation of stable bispecific IgG1 Aran F. Labrijn, Joyce I. Meesters, Patrick Priem et al. · Nature Protocols	25 Sep 2014	148
33	Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells Paul V. Beum, Elizabeth M. Peek, Margaret A. Lindorfer et al. · The Journal of Immunology Open access	13 Aug 2011	144
34	Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial Catherine Thiéblemont et al. · Leukemia Open access	25 Sep 2024	143
35	Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial Meletios Athanasios Dimopoulos et al. · Journal of Clinical Oncology Open access	4 Jan 2023	138
36	Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial Saad Z. Usmani et al. · Nature Medicine Open access	5 Feb 2025	136
37	Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva Thomas Joseph Ketas, Devidas N. Chaturbhuj, Victor M. Cruz Portillo et al. · Pathogens and Immunity Open access	7 Jun 2021	135
38	Stratification of population in NHANES 2009–2014 based on exposure pattern of lead, cadmium, mercury, and arsenic and their association with cardiovascular, renal and respiratory outcomes Xu Yao, Xu Steven Xu, Yaning Yang et al. · Environment International Open access	4 Feb 2021	133
39	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer David S. Hong et al. · Clinical Cancer Research Open access	3 Dec 2019	132
40	Activity of Human IgG and IgA Subclasses in Immune Defense Against Neisseria meningitidis Serogroup B Gestur Vidarsson, W. Ludo van der Pol, Jean M. H. van den Elsen et al. · The Journal of Immunology Open access	May 2001	131
41	Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial Pieter Sonneveld, Asher Alban Chanan-Khan, Katja Christina Weisel et al. · Journal of Clinical Oncology Open access	22 Nov 2022	128
42	Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action Jeroen J. Lammerts van Bueren, Wim K. Bleeker, Henrik O. Bøgh et al. · Cancer Research Open access	Aug 2006	127
43	Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis Paul V. Beum, Margaret A. Lindorfer, Frank J M Beurskens et al. · The Journal of Immunology Open access	Jul 2008	126
44	Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains Jeroen J. Lammerts van Bueren, Theo T. Rispens, Sandra A.B.W. Verploegen et al. · Nature Biotechnology	Jul 2011	125
45	Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces Jürgen Strasser, Rob N. de Jong, Frank J M Beurskens et al. · Nano Letters Open access	6 Jun 2019	120
46	Immunoglobulin A-Mediated Protection againstBordetella pertussisInfection Sandra M. M. Hellwig, Annemiek B. van Spriel, Joop F. P. Schellekens et al. · Infection and Immunity Open access	Aug 2001	120
47	Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma Meletios Athanasios Dimopoulos et al. · New England Journal of Medicine	9 Dec 2024	114
48	Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials Saad Z. Usmani, Hareth Nahi, Torben Plesner et al. · The Lancet Haematology	26 May 2020	110
49	pH as a Driver for Ammonia-Oxidizing Archaea in Forest Soils Barbara Stempfhuber, Marion Engel, Doreen Fischer et al. · Microbial Ecology	10 Dec 2014	95
50	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck Vassiliki Saloura, Ezra E.W. Cohen, Lisa Francesca Licitra et al. · Cancer Chemotherapy and Pharmacology	8 Apr 2014	88

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.